Tissue assessment                                              

Run 10 is now closed. Details for Run 11 will be advertised here in early 2023.

 

Run 10 included tumour assessment for molecular testing for breast cancer, CNS tumours, colorectal/gastrointestinal tract cancers,  lung cancer, melanoma, thyroid tumours and urological tract tumours.  

 

For further details please download Information for Run 10.

 

The assessment of tumour content and cellularity of the tissue samples is critical to deliver high quality molecular testing and allows accurate interpretation of the variants detected.  Tissue-i aids in standardising tumour annotation and assessment.

 

Molecular testing of solid tumour requires accurate selection of tumour regions for microdissection to ensure:

 

• Sample quality
• Sufficiency of tumour DNA
• Precision of test result

 

This histopathology assessment enables individuals to evidence their competency to select appropriate tissue areas for genomic testing.  Participants are required to mark tumour rich regions for macrodissection for molecular testing, and to assess tumour content and cellularity.  It covers a range of tissue types (breast cancer, colorectal cancer/gastrointestinal, lung cancer, central nervous system, melanoma, gynaecological tract, prostate cancer and sarcoma). 

 

Participation in Tissue-i includes:

• Detailed instructions provided

• Clinical case scenario and image provided

• Results assessed by expert panel

• Participants receive an Individual Laboratory Report (ILR), a Summary Assessment report and a Participation certificate

 

To participate in Tissue-i, please contact us. We will require details of your host laboratory for billing purposes, and you will need to state which tumour types you assess for molecular analysis.

 

NHSE GMS labs are centrally funded by NHSE and there is funding available for the devolved nations - please contact us for at info@genqa.org for further details.